Theratechnologies Announces Preliminary Fourth Quarter and Full Fiscal Year 2020 Revenues and Provides Update on R&D Activities
Expects record Q4 and FY 2020 revenues Receives ‘Study May Proceed’ letters from FDA for Phase 3 trial of tesamorelin in NASH and Phase 1 trial of TH1902 in various cancers MONTREAL, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ( …